Tenaya Therapeutics, Inc. (NASDAQ:TNYA) shares are up on Thursday, reflecting a positive market response to a research collaboration agreement with Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY).
• Tenaya Therapeutics shares are powering higher. What’s behind TNYA gains?
The collaboration is focused on discovering human genetic targets for the potential development of treatments for cardiovascular diseases.
Tenaya Therapeutics will validate up to 15 gene targets. It will receive up to $10 million in upfront payments, with potential milestone payments reaching up to $1.13 billion.
Tenaya’s Capabilities
Tenaya uses human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) with high throughput to identify genetic targets, and human-engineered heart tissue and preclinical in vivo models of human disease to validate and characterize potential product candidates.
Collectively, Tenaya’s target …
This post was originally published here
